iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand domestic operations in response to possible tariffs on imported medicines. According to The Wall Street Journal, more than a dozen drugmakers have pledged over $350 billion in U.S. investments this decade to strengthen local supply chains and reduce tariff risks.
GSK (LON:GSK) revealed plans to spend $30 billion in the United States over the next five years, focusing on research, supply-chain infrastructure, and new production facilities. The investment includes $1.2 billion for a new factory near Philadelphia dedicated to developing treatments for respiratory illnesses and cancer. The move positions GSK to boost U.S. drug production while creating new jobs in the biopharma sector.
Meanwhile, Eli Lilly (NYSE:LLY) announced a $5 billion investment to build a state-of-the-art plant near Richmond, Virginia. The facility will specialize in manufacturing monoclonal antibodies and bioconjugates, critical therapies in oncology and immunology. Once operational, the plant is expected to employ approximately 650 workers, enhancing Lilly’s domestic manufacturing footprint and supporting innovation in biologic medicines.
The surge in U.S. pharmaceutical investments comes as the Trump administration considers imposing tariffs on imported drugs, with rates potentially climbing to 250% within 18 months. Such measures could significantly impact global supply chains, pushing companies to accelerate onshore production strategies.
By committing billions to U.S. manufacturing, GSK and Eli Lilly join a broader trend of pharmaceutical giants prioritizing local capacity. These investments are expected to safeguard supply resilience, stimulate job creation, and position drugmakers to better navigate policy changes affecting the global pharmaceutical market.
